CA2725342C - Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders - Google Patents

Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders Download PDF

Info

Publication number
CA2725342C
CA2725342C CA2725342A CA2725342A CA2725342C CA 2725342 C CA2725342 C CA 2725342C CA 2725342 A CA2725342 A CA 2725342A CA 2725342 A CA2725342 A CA 2725342A CA 2725342 C CA2725342 C CA 2725342C
Authority
CA
Canada
Prior art keywords
formula
compound
use according
agonist
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2725342A
Other languages
English (en)
French (fr)
Other versions
CA2725342A1 (en
Inventor
Sharon Mates
Allen A. FIENBERG
Lawrence P. Wennogle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41377435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2725342(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CA2725342A1 publication Critical patent/CA2725342A1/en
Application granted granted Critical
Publication of CA2725342C publication Critical patent/CA2725342C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2725342A 2008-05-27 2009-05-27 Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders Active CA2725342C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5643308P 2008-05-27 2008-05-27
US61/056,433 2008-05-27
US15503209P 2009-02-24 2009-02-24
US61/155,032 2009-02-24
PCT/US2009/003261 WO2009145900A1 (en) 2008-05-27 2009-05-27 Methods and compositions for sleep disorders and other disorders

Publications (2)

Publication Number Publication Date
CA2725342A1 CA2725342A1 (en) 2009-12-03
CA2725342C true CA2725342C (en) 2024-02-20

Family

ID=41377435

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2725342A Active CA2725342C (en) 2008-05-27 2009-05-27 Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders

Country Status (9)

Country Link
US (10) US8598119B2 (enExample)
EP (2) EP3085231A1 (enExample)
JP (2) JP6106361B2 (enExample)
KR (4) KR20110022631A (enExample)
CN (2) CN102105059B (enExample)
AU (1) AU2009251816B2 (enExample)
CA (1) CA2725342C (enExample)
MX (3) MX377802B (enExample)
WO (1) WO2009145900A1 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
KR102107954B1 (ko) 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
AU2009223701B2 (en) 2008-03-12 2015-04-16 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
EP3085231A1 (en) 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
CA2796756A1 (en) * 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
US8741888B2 (en) * 2010-11-09 2014-06-03 Carl A. Forest Sleep aid composition and method
AU2012283035B2 (en) * 2011-07-08 2015-07-30 Eli Lilly & Company (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT2A antagonists
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN103175973B (zh) * 2013-02-26 2015-05-13 首都医科大学 甘丙肽在制备女性抑郁症检测工具中的应用
WO2014159720A1 (en) * 2013-03-13 2014-10-02 The University Of Chicago Methods and compositions for inhibiting glyoxalase 1 (glo1)
WO2014152804A1 (en) * 2013-03-14 2014-09-25 Hyperion Biotechnology Methods and compositions for biomarkers of fatigue, fitness and physical performance capacity
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
CN107206093A (zh) * 2015-01-28 2017-09-26 韩国真耐瑞斯有限公司 用于治疗神经精神类障碍的组合物及方法
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
PL3838274T3 (pl) * 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436455A4 (en) * 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
RU2767410C2 (ru) 2017-03-24 2022-03-17 Интра-Селлулар Терапиз, Инк. Новые композиции и способы
EP3609501A4 (en) * 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
EP3658144B1 (en) 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
US11440911B2 (en) 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
KR102036909B1 (ko) * 2017-11-28 2019-10-25 한국과학기술원 신규 디스토니아 치료용 약학적 조성물
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
US20210008065A1 (en) 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
AU2019280850C1 (en) 2018-06-06 2025-02-13 Intra-Cellular Therapies, Inc. Novel salts and crystals
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
CA3240552A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11806311B2 (en) 2018-06-21 2023-11-07 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CA3110997A1 (en) 2018-09-07 2020-03-12 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
WO2020131899A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Organic compound
US12195463B2 (en) 2018-12-21 2025-01-14 Intra-Cellular Therapies, Inc. Organic compounds
JP7649743B2 (ja) * 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2021007245A1 (en) 2019-07-07 2021-01-14 Intra-Cellular Therapies, Inc. Novel methods
US12478623B2 (en) 2019-09-25 2025-11-25 Intra-Cellular Therapies, Inc. Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor
KR102227268B1 (ko) * 2019-10-07 2021-03-12 한국과학기술원 디스토니아 치료 후보 약물의 신규 스크리닝 방법
KR20220126286A (ko) 2019-11-01 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 전구약물 조성물 및 치료 방법
KR20220126287A (ko) 2019-11-14 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 멀티모달 조성물 및 치료 방법
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
WO2021127572A1 (en) 2019-12-19 2021-06-24 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
MX2023004102A (es) * 2020-10-09 2023-04-27 Shujing Biopharma Co Ltd Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo.
EP4277611A1 (en) 2021-01-15 2023-11-22 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
CA3210706A1 (en) 2021-03-09 2022-09-15 Alexander Mark Schobel Dosage forms having equivalent biocomparable profiles
US20250025572A1 (en) * 2021-11-29 2025-01-23 Editas Medicine, Inc. Engineered crispr/cas12a effector proteins, and uses thereof
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN119486738A (zh) 2022-05-18 2025-02-18 细胞内治疗公司 新方法
CN115067220B (zh) * 2022-06-16 2023-04-25 中国人民解放军军事科学院军事医学研究院 一种双通道小动物恐惧共情行为检测系统
CN120282964A (zh) * 2022-10-26 2025-07-08 上海枢境生物科技有限公司 一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用
WO2024145659A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2024173901A1 (en) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
KR20250129554A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 드로페리돌을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162318A (en) * 1976-05-05 1979-07-24 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of trazodone and etoperidone in Parkinsonism and in other extrapyramidal syndromes characterized by tremors
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
ATE277048T1 (de) 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) * 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
EP1848433A2 (en) 2005-01-25 2007-10-31 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR102107954B1 (ko) 2007-03-12 2020-05-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
MX2010001218A (es) 2007-08-01 2010-04-07 Medivation Neurology Inc Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
EP2250199B1 (en) 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Engineered anti-tslpr antibodies
AU2009223701B2 (en) 2008-03-12 2015-04-16 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
EP3085231A1 (en) * 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9708322B2 (en) * 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
KR102373288B1 (ko) * 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US10077267B2 (en) * 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2944755A1 (en) * 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
PL3838274T3 (pl) * 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
US11014925B2 (en) * 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436455A4 (en) * 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
EP3525763B1 (en) * 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3658144B1 (en) * 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
WO2020047408A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods

Also Published As

Publication number Publication date
KR102317698B1 (ko) 2021-10-25
US20250332164A1 (en) 2025-10-30
JP6106361B2 (ja) 2017-03-29
US20190183888A1 (en) 2019-06-20
CN105168219A (zh) 2015-12-23
CN105168219B (zh) 2018-11-20
US20240041871A1 (en) 2024-02-08
CN102105059A (zh) 2011-06-22
AU2009251816A1 (en) 2009-12-03
KR20110022631A (ko) 2011-03-07
AU2009251816B2 (en) 2015-12-10
CA2725342A1 (en) 2009-12-03
USRE48839E1 (en) 2021-12-07
KR20200134341A (ko) 2020-12-01
WO2009145900A1 (en) 2009-12-03
CN102105059B (zh) 2015-09-30
KR102184038B1 (ko) 2020-11-27
KR20190006606A (ko) 2019-01-18
US20230355616A1 (en) 2023-11-09
US9168258B2 (en) 2015-10-27
EP3085231A1 (en) 2016-10-26
EP2320731A1 (en) 2011-05-18
US20160030425A1 (en) 2016-02-04
MX2010013020A (es) 2011-03-21
HK1219306A1 (zh) 2017-03-31
MX2020012868A (es) 2022-06-14
JP2011523949A (ja) 2011-08-25
EP2320731A4 (en) 2012-09-26
JP2015157828A (ja) 2015-09-03
US20200405713A1 (en) 2020-12-31
US10702522B2 (en) 2020-07-07
US9616061B2 (en) 2017-04-11
MX377802B (es) 2025-03-11
KR102133073B1 (ko) 2020-07-10
US8598119B2 (en) 2013-12-03
US20170189398A1 (en) 2017-07-06
US10117867B2 (en) 2018-11-06
US20140050783A1 (en) 2014-02-20
US20110071080A1 (en) 2011-03-24
KR20160135371A (ko) 2016-11-25

Similar Documents

Publication Publication Date Title
CA2725342C (en) Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
CN112409363B (zh) 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
AU2017393082B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2008329072A1 (en) Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10
AU2005300691A1 (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
AU2015218433B2 (en) Methods and compositions for sleep disorders and other disorders
HK1230864A1 (en) Method and compositions for sleep disorders and other disorders
HK1219306B (zh) 用於睡眠障碍和其他疾病的方法和组合物
HK40097181A (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140523

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20241128

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413